{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:10:56Z","timestamp":1789081856754,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00198-021-05951-1","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:11:57Z","timestamp":1623021117000},"page":"2473-2484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage"],"prefix":"10.1007","volume":"32","author":[{"given":"A.J.","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Stad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yehoshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"5951_CR1","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"key":"5951_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","volume":"29","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA (2018) Hip fracture trends in the United States, 2002 to 2015. Osteoporos Int 29:717\u2013722","journal-title":"Osteoporos Int"},{"key":"5951_CR3","unstructured":"International Osteoporosis Foundation (2020) Osteoporosis facts and statistics. www.iofbonehealth.org\/facts-statistics. Accessed 17 September 2020"},{"key":"5951_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"5951_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"5951_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2015-3156","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD (2016) Underdiagnosis and undertreatment of osteoporosis: the battle to be won. J Clin Endocrinol Metab 101:852\u2013859","journal-title":"J Clin Endocrinol Metab"},{"key":"5951_CR7","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N","volume":"44","author":"SL Silverman","year":"2001","unstructured":"Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation S (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study. Arthritis Rheum 44:2611\u20132619","journal-title":"Arthritis Rheum"},{"key":"5951_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","volume":"6","author":"O Strom","year":"2011","unstructured":"Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jonsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59\u2013155","journal-title":"Arch Osteoporos"},{"key":"5951_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"5951_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","volume":"90","author":"A Singer","year":"2015","unstructured":"Singer A, Exuzides A, Spangler L, O'Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53\u201362","journal-title":"Mayo Clin Proc"},{"key":"5951_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357","journal-title":"Osteoporos Int"},{"key":"5951_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13166","volume":"1376","author":"M Pazianas","year":"2016","unstructured":"Pazianas M, Abrahamsen B (2016) Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least? Ann N Y Acad Sci 1376:5\u201313","journal-title":"Ann N Y Acad Sci"},{"key":"5951_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"5951_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1185\/030079906X167615","volume":"23","author":"DT Gold","year":"2007","unstructured":"Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585\u2013594","journal-title":"Curr Med Res Opin"},{"key":"5951_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"5951_CR16","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00198-018-4630-6","volume":"29","author":"J Liu","year":"2018","unstructured":"Liu J, Guo H, Rai P, Pinto L, Barron R (2018) Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int 29:2409\u20132417","journal-title":"Osteoporos Int"},{"key":"5951_CR17","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26:2401\u20132411","journal-title":"Osteoporos Int"},{"key":"5951_CR18","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1007\/s00198-005-1997-y","volume":"16","author":"JA Pasco","year":"2005","unstructured":"Pasco JA, Sanders KM, Hoekstra FM, Henry MJ, Nicholson GC, Kotowicz MA (2005) The human cost of fracture. Osteoporos Int 16:2046\u20132052","journal-title":"Osteoporos Int"},{"key":"5951_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00774-018-0916-1","volume":"37","author":"S Fujiwara","year":"2019","unstructured":"Fujiwara S, Zhao X, Teoh C, Jaffe DH, Taguchi Y (2019) Disease burden of fractures among patients with osteoporosis in Japan: health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and economic costs. J Bone Miner Metab 37:307\u2013318","journal-title":"J Bone Miner Metab"},{"key":"5951_CR20","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00198-013-2364-z","volume":"24","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907\u20132918","journal-title":"Osteoporos Int"},{"key":"5951_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"5951_CR22","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A, Hiligsmann M, European Society for C, Economic Aspect of Osteoporosis O, Musculoskeletal D (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31:1645\u20131669","journal-title":"Osteoporos Int"},{"key":"5951_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11657-019-0599-9","volume":"14","author":"H Salminen","year":"2019","unstructured":"Salminen H, Piispanen P, Toth-Pal E (2019) Primary care physicians' views on osteoporosis management: a qualitative study. Arch Osteoporos 14:48","journal-title":"Arch Osteoporos"},{"key":"5951_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158365","volume":"11","author":"S Alami","year":"2016","unstructured":"Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C (2016) Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients' and practitioners' views. PLoS One 11:e0158365","journal-title":"PLoS One"},{"key":"5951_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1759720X17732562","volume":"9","author":"WF Lems","year":"2017","unstructured":"Lems WF, Raterman HG (2017) Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Ther Adv Musculoskelet Dis 9:299\u2013316","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5951_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","volume":"12","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12:58","journal-title":"Arch Osteoporos"},{"key":"5951_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11657-018-0491-z","volume":"13","author":"SL Silverman","year":"2018","unstructured":"Silverman SL, Siris E, Belazi D, Recknor C, Papaioannou A, Brown JP, Gold DT, Lewiecki EM, Quinn G, Balasubramanian A, Yue S, Stolshek B, Kendler DL (2018) Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Arch Osteoporos 13:85","journal-title":"Arch Osteoporos"},{"key":"5951_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","volume":"26","author":"SL Silverman","year":"2015","unstructured":"Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26:361\u2013372","journal-title":"Osteoporos Int"},{"key":"5951_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00198-019-04963-2","volume":"30","author":"DM Borek","year":"2019","unstructured":"Borek DM, Smith RC, Gruber CN, Gruber BL (2019) Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. Osteoporos Int 30:1455\u20131464","journal-title":"Osteoporos Int"},{"key":"5951_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11914-006-0011-8","volume":"4","author":"DT Gold","year":"2006","unstructured":"Gold DT, Silverman S (2006) Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 4:21\u201327","journal-title":"Curr Osteoporos Rep"},{"key":"5951_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00198-010-1335-x","volume":"22","author":"S Lee","year":"2011","unstructured":"Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741\u2013753","journal-title":"Osteoporos Int"},{"key":"5951_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"key":"5951_CR33","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.bonr.2020.100267","volume":"12","author":"AD Anastasilakis","year":"2020","unstructured":"Anastasilakis AD, Evangelatos G, Makras P, Iliopoulos A (2020) Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Rep 12:100267","journal-title":"Bone Rep"},{"key":"5951_CR34","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","volume":"130","author":"L Tripto-Shkolnik","year":"2020","unstructured":"Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I (2020) Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone 130:115150","journal-title":"Bone"},{"key":"5951_CR35","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","volume":"30","author":"EM Dennison","year":"2019","unstructured":"Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D, Ferrari S, Group IOFEQoLW (2019) Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 30:1733\u20131743","journal-title":"Osteoporos Int"},{"key":"5951_CR36","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1359\/JBMR.050509","volume":"20","author":"ES Siris","year":"2005","unstructured":"Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514\u20131524","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05951-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T13:02:55Z","timestamp":1637586175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05951-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5951"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05951-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was obtained through the Hennepin Healthcare Research Institute, Office for Human Subjects Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"AS has received research\/grant support from Radius and UCB, paid to MedStar; income from Agnovos, Amgen, Radius, and UCB for consulting\/advisory boards; speaker\u2019s bureau fees from Amgen and Radius; and has also served on the National Osteoporosis Foundation Board of Trustees (non-remunerative). AY, RS, and SRG are Amgen employees and stockholders; JL and HY are employees of CDRG, and CDRG received research support from Amgen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}